A Co-Delivery Strategy of Abemaciclib Combined with Vitamin E Succinate Based on Hyaluronic Acid Modified Calcium Phosphate to Enhance the Anti-Cancer Effect

Abstract Combination therapy including anticancer drugs usually induces synergistic effects, especially in combination with natural compounds as a chemical sensitizer. Nano-based drug delivery technology is also effective in solving the toxicity of single drugs at high doses. In this study, we established a co-delivery strategy for abemaciclib (ABE) combined with vitamin E succinate (VES) based on HA-modified calcium phosphate (CaP) nanomaterials to enhance anti-cancer effect. The nano-sized HA/CaP particles (90 nm) have a hollow structure. Surprisingly, after modification with HA, HA/CaP has more pH sensitivity. CaP released 30% ABE and 91% VES at pH 7.4, whereas HA/CaP vsreleased 14% ABE and 32% VES at the same pH. Cell experiments showed that HA/CaP/ABE-VES had stronger cell inhibitory effect on MCF-7 compared with CaP/ABE-VES. This inorganic/organic composite for the co-delivery of ABE and VES has obvious tumor inhibition effect, and is ideal for anti-tumor drug delivery.